ABSTRACT
AIM: Rapidly expanding manufacture and use of nanomaterials emphasize the requirements for thorough assessment of health outcomes associated with novel applications. Post-translational protein modifications catalyzed by Ca(2+)-dependent peptidylargininedeiminases have been shown to trigger immune responses including autoantibody generation, a hallmark of immune complexes deposition in rheumatoid arthritis. Therefore, the aim of the study was to assess if nanoparticles are able to promote protein citrullination. MATERIALS & METHODS: Human A549 and THP-1 cells were exposed to silicon dioxide, carbon black or single-walled carbon nanotubes. C57BL/6 mice were exposed to respirable single-walled carbon nanotubes. Protein citrullination, peptidylargininedeiminases activity and target proteins were evaluated. RESULTS: The studied nanoparticles induced protein citrullination both in cultured human cells and mouse lung tissues. Citrullination occurred via the peptidylargininedeiminase-dependent mechanism. Cytokeratines 7, 8, 18 and plectins were identified as intracellular citrullination targets. CONCLUSION: Nanoparticle exposure facilitated post-translational citrullination of proteins.
Subject(s)
Carbon/metabolism , Citrulline/metabolism , Nanostructures/administration & dosage , Proteins/metabolism , Silicon Dioxide/metabolism , Soot/metabolism , Animals , Calcium/metabolism , Carbon/administration & dosage , Cell Line , Female , Humans , Hydrolases/antagonists & inhibitors , Hydrolases/metabolism , Lung/drug effects , Lung/metabolism , Mice , Mice, Inbred C57BL , Nanostructures/chemistry , Nanotubes, Carbon/chemistry , Protein Processing, Post-Translational , Protein-Arginine Deiminases , Silicon Dioxide/administration & dosage , Soot/administration & dosageABSTRACT
INTRODUCTION: Protein citrullination is present in the rheumatoid synovium, presumably contributing to the perpetuation of chronic inflammation, in the presence of specific autoimmunity. As a result, the present study examined the possibility that effective antirheumatic treatment will decrease the level of synovial citrullination. METHODS: Synovial biopsies were obtained from 11 rheumatoid arthritis (RA) patients before and after 8 weeks of treatment with 20 mg methotrexate weekly, 15 RA patients before and 2 weeks after an intraarticular glucocorticoid injection, and eight healthy volunteers. Synovial inflammation was assessed with double-blind semiquantitative analysis of lining thickness, cell infiltration, and vascularity by using a 4-point scale. Expression of citrullinated proteins (CPs) with the monoclonal antibody F95 and peptidylarginine deiminase (PAD) 2 and 4 was assessed immunohistochemically with double-blind semiquantitative analysis. In vitro synovial fluid (SF), peripheral blood (PB), mononuclear cells (MCs), and synovial explants obtained from RA patients were incubated with dexamethasone and analyzed with immunohistochemistry for expression of CP as well as PAD2 and PAD4 enzymes. RESULTS: The presence of synovial CP was almost exclusive in RA compared with healthy synovium and correlated with the degree of local inflammation. Treatment with glucocorticoids but not methotrexate alters expression of synovial CP and PAD enzymes, in parallel with a decrease of synovial inflammation. Ex vivo and in vitro studies suggest also a direct effect of glucocorticoids on citrullination, as demonstrated by the decrease in the level of citrullination and PAD expression after incubation of SFMC and synovial explants with dexamethasone. CONCLUSION: Synovial citrullination and PAD expression are dependent on local inflammation and targeted by glucocorticoids.
Subject(s)
Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Citrulline/metabolism , Glucocorticoids/therapeutic use , Synovial Membrane/drug effects , Adult , Aged , Aged, 80 and over , Antirheumatic Agents/administration & dosage , Arthritis, Rheumatoid/metabolism , Arthritis, Rheumatoid/pathology , Dexamethasone/administration & dosage , Dexamethasone/therapeutic use , Double-Blind Method , Female , Glucocorticoids/administration & dosage , Humans , Hydrolases/metabolism , Immunohistochemistry , Injections, Intra-Articular , Male , Methotrexate/administration & dosage , Methotrexate/therapeutic use , Middle Aged , Peptides/metabolism , Protein-Arginine Deiminase Type 2 , Protein-Arginine Deiminase Type 4 , Protein-Arginine Deiminases , Synovial Membrane/metabolism , Synovial Membrane/pathology , Time Factors , Tissue Culture Techniques , Treatment Outcome , Triamcinolone Acetonide/administration & dosage , Triamcinolone Acetonide/analogs & derivatives , Triamcinolone Acetonide/therapeutic useABSTRACT
The presence or absence of antibodies to citrullinated peptides/proteins (ACPA) is an important parameter that helps a clinician set a diagnosis of early rheumatoid arthritis and, hence, initiate treatment. There are several commercial tests available to measure ACPA levels, although it can be difficult to decide what the best test for a given clinical question is. We analyzed literature data in which the diagnostic and other properties of various ACPA tests are compared. The results show that for diagnostic purposes the CCP2 test has the highest specificity, the highest sensitivity in stratified studies and the highest positive predictive value. For the prediction of future joint destruction the CCP2, MCV, and CCP3 tests may be used. The ability to predict the likelihood of not achieving sustained disease-modifying antirheumatic drug-free remission was highest for the CCP2 test. Finally, the levels of anti-CCP2 and anti-CCP3 (and possibly anti-mutated citrullinated vimentin) in rheumatoid arthritis patients are not significantly influenced by TNFalpha blocking agents.
Subject(s)
Arthritis, Rheumatoid/diagnosis , Autoantibodies/analysis , Citrulline/metabolism , Immunoassay/methods , Peptides , Proteins , Animals , Arthritis, Rheumatoid/metabolism , Autoantibodies/blood , Autoantigens/immunology , Biomarkers/analysis , Biomarkers/metabolism , Humans , Peptides/metabolism , Proteins/metabolism , Sensitivity and SpecificityABSTRACT
INTRODUCTION: Patients with tuberculosis (TB) frequently produce anti-citrullinated protein antibodies (ACPA). The objective of this study is to characterize the citrulline-dependence of the ACPA reactivity in sera of patients with mycobacterium infections. METHODS: Serum samples of 134 patients with untreated mycobacterium infections (122 TB, 12 nontuberculous mycobacterium) were tested for antibodies against both the citrullinated (Cit) and the non-citrullinated (Arg) form of 2 cyclic synthetic peptides. In 33 patients, a follow-up sample was tested six months after starting anti-mycobacterial drugs. RESULTS: A substantial proportion of patients with mycobacterial infections demonstrated antibodies against 0401Cit, 0401Arg, 0722Cit and 0722Arg. Fourteen patients demonstrated anti-0401Cit, 83 anti-0401Arg, 22 anti-0722Cit and 61 anti-0722Arg, while none of these antibodies were detected in the 20 healthy controls. All the patients but one, who were anti-0401Cit and anti-0722Cit positive, demonstrated reactivity against the respective Arg peptide. In the subset of 33 patients with a follow-up test six months after starting treatment, the mean levels of antibodies to 0401Cit, 0401Arg, 0722Cit and 0722Arg significantly decreased after treatment. All the patients who were anti-0401Cit and anti-0722Cit positive turned negative after treatment. The presence of anti-0401Cit/Arg and anti-0722Cit/Arg was found to be significantly correlated with the presence of HIV. CONCLUSIONS: ACPA may be found in patients with TB. In most of the cases, the reactivity is citrulline independent. A positive cyclic citrullinated peptide (CCP) test in these patients should therefore be interpreted with care, and preferably followed by a control ELISA with a non-citrullinated antigen.